SEARCH

SEARCH BY CITATION

References

  • Aglietta, M., Montemurro, F., Fagioli, F., Volta, C., Botto, B., Cantonetti, M., Racanelli, V., Teofili, L., Ferrara, R., Amadori, S., Castoldi, G.L., Dammacco, F. & Levis, A. (2000) Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. Cancer, 88, 454460.
  • Armitage, J.O. (1993) Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 10231030.
  • Aviles, A., Diaz-Maqueo, J.C., Talavera, A., Nambo, M.J. & Garcia, E.L. (1994) Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy. Leukemia and Lymphoma, 15, 153157.
  • Barbui, T., Finazzi, G., Grassi, A. & Marchioli, R. (1996) Thrombosis in cancer patients treated with hematopoietic growth factors - a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thrombosis and Haemostasis, 75, 368371.
  • Bastion, Y., Bosly, A., Gisselbrecht, C., Reyes, F., Tilly, H. & Herbrecht, R. (1993) A randomized double-blind phase III study of Filgrastim (recombinant human G-CSF) vs placebo during intensive induction chemotherapy in 55–69-year old patients (pts) with poor prognosis aggressive Non-Hodgkin's Lymphoma. Blood, 82, 143a.
  • Beveridge, R.A., Miller, J.A., Kales, A.N., Binder, R.A., Robert, N.J., Harvey, J.H., Windsor, K., Gore, I., Cantrell, J., Thompson, K.A., Taylor, W.R., Barnes, H.M., Schiff, S.A., Shields, J.A., Cambareri, R.J., Butler, T.P., Meister, R.J., Feigert, J.M., Norgard, M.J., Moraes, M.A., Helvie, W.W., Patton, G.A., Mundy, L.J., Henry, D. & Sheridan, M.J. (1998) A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Investigations, 16, 366373.
  • Björkholm, M., Osby, E., Hagberg, H., Kvaloy, S., Teerenhovi, J. & Myhre, J. (1999) Randomized trial of r-met-Hu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive Non-Hodgkin's Lymphoma. Blood, 94, 599a.
  • Bodey, G.P., Buckley, M., Sathe, Y.S. & Freireich, E.J. (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine, 64, 328340.
  • Bohlius, J., Reiser, M., Schwarzer, G. & Engert, A. (2002) Granulopoiesis-stimulating factors in the prevention of adverse effects in the chemotherapeutic treatment of malignant lymphoma. In: The Cochrane Library, Issue 4, 2002.
  • Bronchud, M.H., Potter, M.R., Morgenstern, G., Blasco, M.J., Scarffe, J.H., Thatcher, N., Crowther, D., Souza, L.M., Alton, N.K. & Testa, N.G. (1988) In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. British Journal of Cancer, 58, 6469.
  • Diehl, V., Franklin, J., Sieber, M., Hasenclever, D., Wolf, J. & Engert, A. (2000) Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's Disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood, 96, 576a.
  • Doorduijn, J.K., Van Der Holt, B., Van Der Hem, K.G., Van Imhoff, G.W., Kramer, M.H.H. & Van Oers, M.H.J. (2000) Randomized trial of granulocyte-colony stimulating factor (G-CSF) added to CHOP in elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Blood, 96, 133a.
  • Dunlop, D.J., Eatock, M.M., Paul, J., Anderson, S., Reed, N.S., Soukop, M., Lucie, N., Fitzsimmons, E.J., Tansey, P. & Steward, W.P. (1998) Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clinical Oncology (Royal College of Radiology), 10, 107114.
  • Egger, M., Davey, S.G., Schneider, M. & Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. British Medical Journal, 315, 629634.
  • Engelhard, M., Gerhartz, H., Brittinger, G., Engert, A., Fuchs, R., Geiseler, B., Gerhartz, D., Haunauske, A.R., Hartlapp, H.J. & Huhn, D. (1994) Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF. Annals of Oncology, 5, 123125.
  • Fridrik, M.A., Greil, R., Hausmaninger, H., Krieger, O., Oppitz, P., Stoger, M., Klocker, J., Neubauer, M., Helm, W., Pont, J., Fazeny, B., Hudec, M., Simonitsch, I. & Radaszkiewicz, T. (1997) Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy. Annals of Hematology, 75, 135140.
  • Gerhartz, H.H., Engelhard, M., Meusers, P., Brittinger, G., Wilmanns, W., Schlimok, G., Mueller, P., Huhn, D., Musch, R. & Siegert, W. (1993) Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood, 82, 23292339.
  • Gerhartz, H.H., Engelhard, M., Brittinger, G., Schlimok, G., Thiel, E., Huber, C., Emmerich, B., Schadek, C., Brandmaier, R. & Stern, A.C. (1994) Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas. Seminars in Oncology, 21, 2528.
  • Gisselbrecht, C., Haioun, C., Lepage, E., Bastion, Y., Tilly, H., Bosly, A., Dupriez, B., Marit, G., Herbrecht, R., Deconinck, E., Marolleau, J.P., Yver, A., Dabouz-Harrouche, F., Coiffier, B. & Reyes, F. (1997) Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leukemia and Lymphoma, 25, 289300.
  • Goldie, J.H. & Coldman, A.J. (1983) Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treatment Report, 67, 923931.
  • De Graaf, H., Willemse, P.H., Bong, S.B., Piersma, H., Tjabbes, T., Van Veelen, H., Coenen, J.L. & De Vries, E.G. (1996) Dose intensity of standard adjuvant CMF with granulocyte colony- stimulating factor for premenopausal patients with node-positive breast cancer. Oncology, 53, 289294.
  • Gregory, S., Goh, Y.T., Fuerst, M.P., O'Brien, T. & Giles, F.J. (1998) Fludarabine (F), Cyclophosphamide (C), and GM-CSF (FCGM) is effective in chronic lymphatic leukemia (CLL) and low grade non Hodgkins lymphoma (LGNHL). Blood, 92, 276b.
  • Hryniuk, W. & Bush, H. (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology, 2, 12811288.
  • Lepage, E., Gisselbrecht, C., Haioun, C., Sebban, C., Tilly, H., Bosly, A., Morel, P., Herbrecht, R., Reyes, F. & Coiffier, B. (1993) Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomes de l'Adulte). Annals of Oncology, 4, 651656.
  • Liberati, A.M., Cinieri, S., Schippa, M., Di Clemente, F., Filippo, S. & Grignani, F. (1991) GM-CSF: clinical trials in non-Hodgkin's lymphoma patients with chemotherapy induced leucopenia. Leukemia, 5, 119122.
  • Lopez, A.F., Williamson, D.J., Gamble, J.R., Begley, C.G., Harlan, J.M., Klebanoff, S.J., Waltersdorph, A., Wong, G., Clark, S.C. & Vadas, M.A. (1986) Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. Journal of Clinical Investigations, 78, 12201228.
  • Lyman, G.H., Kuderer, N.M. & Djulbegovic, B. (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer. American Journal of Medicine, 112, 406411.
  • Magrath, I., Adde, M., Shad, A., Venzon, D., Seibel, N., Gootenberg, J., Neely, J., Arndt, C., Nieder, M., Jaffe, E., Wittes, R.A. & Horak, I.D. (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology, 14, 925934.
  • Ozer, H., Armitage, J.O., Bennett, C.L., Crawford, J., Demetri, G.D., Pizzo, P.A., Schiffer, C.A., Smith, T.J., Somlo, G., Wade, J.C., Wade, III, J.L., Winn, R.J., Wozniak, A.J. & Somerfield, M.R. (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. Journal of Clinical Oncology, 18, 35583585.
  • Parmar, M.K., Torri, V. & Stewart, L. (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine, 17, 28152834.
  • Pettengell, R., Gurney, H., Radford, J.A., Deakin, D.P., James, R., Wilkinson, P.M., Kane, K., Bentley, J. & Crowther, D. (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood, 80, 14301436.
  • Pettengell, R., Testa, N.G., Swindell, R., Crowther, D. & Dexter, T.M. (1993) Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood, 82, 22392248.
  • Pfreundschuh, M. (2001) 2-weekly CHOP (CHOP-14): the new standard for patients with aggressive Non Hodgkin's lymphoma (NHL) > 60 years of age. Blood, 98, #3027.
  • Rusthoven, J., Bramwell, V. & Stephenson, B. (1998) Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group. Cancer Prevention and Control, 2, 179190.
  • Skipper, H.E. (1990) Dose intensity versus total dose of chemotherapy: an experimental basis. In: Important Advances in Oncology (ed. by V. DeVita Jr, S. Hellman & S.A. Rosenberg), pp. 4364. J.B. Lippincott Company, Philadelphia.
  • Souetre, E. & Qing, W. (1994) Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma. Pharmacoeconomics, 6, 3643.
  • Sweetenham, J.W., Hackshaw, A. & Knight, A. (2000) Evidence-based review and meta-analysis of the use of hematopoietic growth factors (HGF) in the management of malignant lymphoma (ML). Blood, 96, 139a.
  • Woll, P.J., Hodgetts, J., Lomax, L., Bildet, F., Cour-Chabernaud, V. & Thatcher, N. (1995) Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. Journal of Clinical Oncology, 13, 652659.
  • Yau, J.C., Neidhart, J.A., Triozzi, P., Verma, S., Nemunaitis, J., Quick, D.P., Mayernik, D.G., Oette, D.H., Haynes, F.A. & Holcenberg, J. (1996) Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. American Journal of Hematology, 51, 289295.
  • Zinzani, P.L., Pavone, E., Storti, S., Moretti, L., Fattori, P.P., Guardigni, L., Falini, B., Gobbi, M., Gentilini, P., Lauta, V.M., Bendandi, M., Gherlinzoni, F., Magagnoli, M., Venturi, S., Aitini, E., Tabanelli, M., Leone, G., Liso, V. & Tura, S. (1997) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non- Hodgkin's lymphoma. Blood, 89, 39743979.
  • Zinzani, P.L., Storti, S., Zaccaria, A., Moretti, L., Magagnoli, M., Pavone, E., Gentilini, P., Guardigni, L., Gobbi, M., Fattori, P.P., Falini, B., Lauta, V.M., Bendandi, M., Gherlinzoni, F., De Renzo, A., Zaja, F., Mazza, P., Volpe, E., Bocchia, M., Aitini, E., Tabanelli, M., Leone, G. & Tura, S. (1999) Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood, 94, 3338.